GENETIC SIGNATURES LIMITED (GSS)
Share Price Analysis and Chart

01/11/2024

1

Speculative Buy

$1.10

74.60%

Genetic Signatures reported a "strong" 1Q25 result, notes Bell Potter, with sales advancing 194% year-on-year and up 4% on the quarter.

Australian sales, excluding covid-specfic tests, were in line following the resolution of FluB test issues. 

Bell Potter believes the rollout in the US of the first diagnostic test is "critical" to the investment case for the company. No US sales have been reported yet, the analyst notes, with expectations of sales in 1H25.

The Speculative Buy rating and $1.10 target are maintained. No change to EPS forecasts.

FORECAST
Bell Potter forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -4.80 cents.
Bell Potter forecasts a full year FY26 dividend of 0.00 cents and EPS of 1.34 cents.

23/05/2024

2

Speculative Outperform

$2.21

250.79%

In a potentially transformational milestone, Taylor Collison points out the final stage is approaching for FDA review of Genetic Signatures' 510(k) application.

The company is seeking clearance to market its EasyScreen gastrointestinal parasite (GIP) test kit in the US. If approved, the analyst is expecting a rapid take-up as the test meets an unmet need, and reimbursement at US$263/test is already in place.

While the broker is expecting a decision before the end of May, there is a moderate risk the FDA review could continue into June.

The Speculative Outperform rating is maintained. Target $2.21.

FORECAST
Taylor Collison forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -5.40 cents.